The company said it recorded a net loss of $784.8 million (net loss of $3.86 per basic and diluted share) for the 3 months ended September 30, 2026, compared with net income of $424.2 million in the same period a year earlier. Net income for the 9 months was $104.1 million, compared with $987.4 million in the same period last year.

1. 01

   The company said it recorded a net loss of $784.8 million (net loss of $3.86 per basic and diluted share) for the 3 months ended September 30, 2026, compared with net income of $424.2 million in the same period a year earlier. Net income for the 9 months was $104.1 million, compared with $987.4 million in the same period last year.

2. 02

   The company said it completed its acquisition of Vega Therapeutics Inc. in July 2026 and that its research and development expenses for the 3 and 9 months included $1.23 billion in acquired in-process research and development asset costs related to the Vega acquisition. The company explained that this amount was a one-time, non-deductible charge that negatively affected its effective tax rate.

3. 03

   The company said the increase in JAKAFI net revenue in Q3 2026 consisted of a volume increase of $102.8 million and a price decline of $67.4 million, and that the volume increase was mainly driven by a 12% increase in patient demand. The company also said that in Q2, it recognized a one-time, non-cash benefit of $246.0 million in OPZELURA net revenue from a settlement with CMS.

4. 04

   The company said that as of September 30, 2026, its cash, cash equivalents and marketable securities totaled $3.9 billion. Net cash provided by operating activities for the 9 months was $201.7 million, down from $870.2 million in the same period a year earlier, which the company attributed mainly to cash consideration paid for the Vega acquisition.

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Structured SEC financial data for this filing is not available yet. Please check the figures in the SEC filing.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.